A first-of-its-kind Psychedelic Genetic Test Kit designed to give individuals an idea of how they will respond to psychedelic treatment and their risk for adverse events is now available in the United States.
The Psychedelic Genetic Test Kit analyzes a series of relevant DNA biomarkers along with pre-screening mental health surveys to provide insight into an individual’s risk and potential for adverse reactions to psychedelic medicine. The kit was created by HaluGen Life Sciences, a wholly-owned subsidiary of the Entheon Biomedical Corp., a biotech company that develops psychedelic medicines to treat addiction.
The Psychedelic Genetic Test Kit provides users with personalized reports so they can make better informed decisions about psychedelic-assisted therapy. “For example, genetics can play a key role in determining how an individual may respond to psychedelic-assisted psychotherapy. The kit also provides them with insights into the short- and long-term potential for psychedelic-induced risks such as psychosis.
For example, “the HTR2A gene mutation, carried by approximately 20% of the population, can impact how a person responds to serotonin, which is the primary mechanism of action for serotonergic psychedelics such as psilocybin, LSD and DMT. Another gene, CYP2B6, can influence the metabolism of ketamine for the 10-20% of people that carry a specific CYP2B6 gene variant,” the company said in a news release.
Once the DNA sample and survey responses are collected from the kit user, the company sends the results directly to the consumer’s smartphone or desktop computer through the HaluGen website platform.
“The launch of this kit into the U.S. market is a significant milestone for the Company, and one that is sure to drive awareness of HaluGen’s Test Kit and the overall potential of personalized tools for use in preparation of psychedelic treatment,” said Timothy Ko, Chief Executive Officer of Entheon. “As individuals look to optimize their own experiences and outcomes as they explore the potential for psychedelic therapy, the US marketplace offers a strong opportunity to expand awareness and to develop key partnerships with those servicing the psychedelic medicine space.”
